Table 1.
CTC and treatment response data in the TARIBO case series.
| CTC by DEPArray | AdnaTest | Clinical Outcomes | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Patient ID | Time | eCTC | ncCTC | CTC tot | CTC Status | Response | PD | PFS (mos) * | DEATH | OS (mos) |
| K009 | preS | 1 | 0 | 1 | pos | PD | yes | 4.14 | yes | 8.98 |
| postS | 0 | 1 | 1 | pos | ||||||
| DT | 0 | 0 | 0 | pos | ||||||
| K012 | preS | 0 | 1 | 1 | neg | SD | yes | 13.22 | yes | 22.07 |
| postS | 0 | 3 | 3 | pos | ||||||
| DT | 0 | 0 | 0 | pos | ||||||
| progress | 1 | 0 | 1 | neg | ||||||
| K016 | preS | / | / | / | / | RP | no | 28.22 | no | 28.22 |
| postS | 0 | 0 | 0 | neg | ||||||
| DT | neg | |||||||||
| K017 | preS | 2 | 2 | 4 | neg | PD | yes | 4.74 | no | 20.13 |
| postS | neg | |||||||||
| progress | 9 | 3 | 12 | neg | ||||||
| K008 | BL | 0 | 0 | 0 | neg | SD | yes | 36.32 | no | 48.06 |
| DT | 1 | 2 | 3 | neg | ||||||
| K010 | BL | 0 | 2 | 2 | neg | NA | NA | yes | 3.39 | |
| K011 | BL | 0 | 1 | 1 | pos | SD | yes | 42.83 | no | 42.83 |
| DT | 0 | 1 | 1 | neg | ||||||
| K013 | BL | 0 | 2 | 2 | neg | NA | NA | yes | 7.99 | |
| K014 | BL | 0 | 0 | 0 | neg | PD | yes | 5.56 | no | 8.75 |
| DT | 0 | 1 | 1 | neg | ||||||
| K015 | BL | 0 | 2 | 2 | pos | PD | yes | 8.222 | yes | 26.84 |
| DT | 1 | 1 | 2 | neg | ||||||
| progress | 0 | 0 | 0 | pos | ||||||
* months. CTC and treatment response data in the TARIBO case series. Abbreviations: CTC, circulating tumor cells; eCTC, epithelial CTC; ncCTC, non-conventional CTC; PFS, progression free survival; OS, overall survival; preS, pre-surgery; postS, post-surgery; DT, 24 h after randomization; BL, baseline; PD, progression disease; SD, stable disease; NA, not available.